Dissecting breast cancer biomarkers in practice: Key insights for surgeons
Surgical Chronicles, cilt.29, sa.3, ss.266-275, 2024 (Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 29 Sayı: 3
- Basım Tarihi: 2024
- Dergi Adı: Surgical Chronicles
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.266-275
- Anahtar Kelimeler: biomarker, cancer, oestrogen, progesterone, receptor, Βreast
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Breast cancer, which is the most prevalent cancer affecting women worldwide, stands as a significant contributor to cancer-related deaths. The American Joint Committee on Cancer has adopted a comprehensive approach to breast cancer staging, which now integrates biomarkers like ER, PR, HER2, and tumour grade alongside the traditional T, N, and M staging system. Biomarkers have emerged as key players in patient management, aiding in the selection of optimal systemic therapies. Physicians, especially those involved in breast cancer care, must acknowledge the critical role of biomarkers. Assessing the status of ER, PR, and HER2, with particular attention to Ki-67 and CDK4/6, is essential for guiding treatment decisions and predicting outcomes. This review aims to offer concise insights tailored to breast surgeons, general surgeons, and physicians, with the goal of enhancing understanding regarding the complexities surrounding the use of breast cancer biomarkers in everyday clinical practice.